- ESHAP Salvage Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
-
Choi CW, Paek CW, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS
- KMID: 1127252
- J Korean Med Sci.
- 2002 Oct;17(5):621-624.
- doi: 10.3346/jkms.2002.17.5.621
The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has been shown to be active against refractory or relapsed non-Hodgkin's lymphoma... -
- CITED
-
- Close
- SHARE
-
- Close
- Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study
-
Baek JH, Kim JG, Sohn SK, Kim DH, Lee KB, Song HS, Kwon KY, Do YR, Ryoo HM, Bae SH, Park KU, Kim MK, Lee KH, Hyun MS, Chung HY, Yu W
- KMID: 2157746
- J Korean Med Sci.
- 2005 Dec;20(6):966-970.
- doi: 10.3346/jkms.2005.20.6.966
The current phase II study was conducted to evaluate the response rate and safety of a combination regimen of biweekly irinotecan plus cisplatin in pretreated patients with advanced gastric cancer.... -
- CITED
-
- Close
- SHARE
-
- Close
